Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02476955 · ClinicalTrials.gov registry record · Phase 1
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
A Phase 1 study, sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA).
- Terminated
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT02476955: Clinical Trial Phase 1 study, sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA).
NCT02476955 is a Phase 1 study that was terminated before completion, run by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA). The registered enrollment target is 41 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02476955, a Phase 1 study, was terminated before completion, sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
An Open-label Phase 1b Study of ARQ 092 in Combination with other Antineoplastic Agents in Subjects with Selected Solid Tumors
Primary Outcome
The incidence of adverse events will be assessed as a measure of the safety and tolerability profile of ARQ 092
Interventions
- DRUG ARQ 092 + carboplatin + paclitaxel (Closed)
- DRUG ARQ 092 + paclitaxel (Closed)
- DRUG ARQ 092 + anastrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2015-06-09 |
| Est. Completion | 2019-05-07 |
| Phase | Phase 1 |
Why NCT02476955 stopped before completion
NCT02476955 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 3 interventions - of which ARQ 092 + carboplatin + paclitaxel (Closed) is the first listed.
NCT02476955 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02476955 about?
NCT02476955 is a clinical study titled "Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole". An Open-label Phase 1b Study of ARQ 092 in Combination with other Antineoplastic Agents in Subjects with Selected Solid Tumors
What is the current status of trial NCT02476955?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2015-06-09. Estimated completion is 2019-05-07.
What interventions are being tested in trial NCT02476955?
The interventions under investigation include: ARQ 092 + carboplatin + paclitaxel (Closed) (DRUG), ARQ 092 + paclitaxel (Closed) (DRUG), ARQ 092 + anastrozole (DRUG).
Who is sponsoring clinical trial NCT02476955?
This trial is sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02476955's enrollment target sits among peer trials
41 1125th of 2000 higher than 871 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI